GSK-7975A is primarily utilized in research settings as a potent and selective inhibitor of the NLRP3 inflammasome. Its application is significant in studying inflammatory diseases, as it helps to block the activation of NLRP3, which is implicated in conditions such as gout, type 2 diabetes, Alzheimer's disease, and atherosclerosis. By inhibiting this pathway, researchers can better understand the role of NLRP3 in disease progression and explore potential therapeutic strategies. Additionally, GSK-7975A is used in preclinical studies to investigate the effects of NLRP3 inhibition on immune responses and inflammation-related cellular processes. Its use contributes to the development of targeted anti-inflammatory treatments.